Dermatologists are in the unique position to be able to diagnose serious systemic diseases through skin findings; in addition, cutaneous manifestations can be associated with internal symptoms and clarify the pathogenesis and treatment of challenging new syndromes.
Hidradenitis suppurativa (HS) is a disease that must be considered and treated in a context much broader than just the consideration of skin lesions and sinus tracts. Clinicians who diagnose HS also must recognize and be prepared to manage the significant comorbidities and complications associated with this chronic, debilitating disease.
The treatment options for patients with hidradenitis suppurativa (HS) include both surgical and medical modalities.
This article reviews the most recent evidence on the efficacy and safety of the TNF inhibitors in psoriasis, with special attention to preventing and managing immunogenicity.